Risperidone
Product
Braeburn Pharmaceuticals, Inc.
Total Payments
$2.2M
Transactions
20
Doctors
2
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $2.2M | 20 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.1M | 15 | 98.4% |
| Consulting Fee | $34,020 | 3 | 1.6% |
| Travel and Lodging | $641.81 | 2 | 0.0% |
Payments by Type
Research
$2.1M
15 transactions
General
$34,662
5 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| BB-RSP-301 | Braeburn Pharmaceuticals, Inc. | $1.3M | 0 |
| BB-PK-103 | Braeburn Pharmaceuticals, Inc. | $802,431 | 0 |
Ad
Manufacturing Companies
Product Information
- Type Product
- Total Payments $2.2M
- Total Doctors 2
- Transactions 20
About Risperidone
Risperidone is a product associated with $2.2M in payments to 2 healthcare providers, recorded across 20 transactions in the CMS Open Payments database. The primary manufacturer is Braeburn Pharmaceuticals, Inc..
Payment data is available from 2017 to 2017. In 2017, $2.2M was paid across 20 transactions to 2 doctors.
The most common payment nature for Risperidone is "Unspecified" ($2.1M, 98.4% of total).
Risperidone is associated with 2 research studies, including "BB-RSP-301" ($1.3M).